Author: Dino Mustafić

October 14, 2022 Off

Clinical trial labels across the globe – how to manage translations and country specific regulations

By Dino Mustafić

In recent years, there has been an industry-wide recognition of the need for speed and agility. Accelerating the trial processes for COVID-19 vaccine candidates required proactive and cooperative efforts from participants at all points in the supply chain. A sense of urgency and an expectation that trials should be completed more quickly and effectively emerged as a result of the realization that a drug can be approved and released to the market in a relatively short period of time. In light of this, improving the speed, accuracy, and agility of clinical trials labeling — and more specifically, the translation of label content — is one of the crucial areas that would help organizations to achieve this. 

October 12, 2022 Off

Sanofi, Regeneron: first and only Phase 3 trial in children with EoE shows positive results

By Dino Mustafić

Dupixent presented detailed data at this year’s UEG Week conference in Vienna from from an investigational Phase 3 trial showing positive results in children ages 1 to 11 years old who are living with eosinophilic esophagitis (EoE). EoE is a chronic, progressive inflammatory disease that damages the esophagus and prevents it from working properly. Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE, approximately 9,000 are most in need of new treatment options.

October 12, 2022 Off

Vetter drives its sustainability campaign forward

By Dino Mustafić

Vetter, a globally leading contract development and manufacturing organization (CDMO) with long-term experience in supporting biotechnology and pharmaceutical customers, has in place a comprehensive sustainability strategy that has made it a pioneer in this energy-intensive industry.

October 12, 2022 Off

Ginkgo in a deal with Merck

By Dino Mustafić

Enzyme biocatalysts can reduce costly synthesis and purification steps, thereby decreasing production costs. Through this collaboration, we aim to optimize…